Henry L. Wong, PhD

Research Associate Professor, Institute for Therapeutics Discovery and Development (ITDD)

Henry L. Wong

Contact Info

hlwong@umn.edu

Office Phone 612-626-6323

Office Address:
Inst for Therapeutics Disc and Dev
455, 717 Delaware St SE
Minneapolis, MN 55414

Mailing Address:
College of Pharmacy
717 Delaware St SE
Minneapolis, MN 55414

Research Associate Professor, Institute for Therapeutics Discovery and Development (ITDD)

Research Associate Professor, Department of Medicinal Chemistry

Associate Program Director - Pharmacology and Biomarkers, Institute for Therapeutics Discovery and Development (ITDD)


Hoffman-LaRoche/Roche Institute of Molecular Biology

PhD, Case Western Reserve University/Cleveland Clinic Foundation (Biology/Immunology)

BSc, Brooklyn College (Biology - cum laude)

Summary

Dr. Wong has broad experience as a bench scientist in both academic and biotech/pharmaceutical settings with an emphasis in drug discovery and development of both small molecules and biologics. Originally trained as a cellular immunologist who focused on the interaction of regulatory T-cells with cytokines and effector cells that occurred during the cell-mediated immune response, Dr. Wong’s interests began to shift when he elected to enter one of the first post-doctoral programs offered by the pharmaceutical industry at Hoffmann-LaRoche in Nutley, NJ. While conducting basic research on the biological and biochemical characterization of a novel cytokine, Dr. Wong was also introduced to the drug discovery/development process where he was responsible for developing in vivo pharmacodynamic animal models for lead optimization of immunosuppressive drugs for transplant rejection.

Following his tenure at Roche, Dr. Wong chose to re-enter academia with an appointment at the NIH (Bethesda, MD) where he continued to investigate regulation of cellular interactions by cytokines. During this period, he had the opportunity to collaborate with clinicians and had initial experiences with clinical cancer research. Following his return to industry, Dr. Wong has focused on oncology and immunology/inflammation drug discovery and development programs either as a member or leader of multi-disciplinary project teams. This has enabled him to be involved in all aspects of drug development from target identification, screening, lead optimization, proof of concept, efficacy, PK/PD, mechanism of action, biomarker development to the planning of Phase I clinical strategies. Successful programs where Dr. Wong has played a role in pre-clinical pharmacology and biomarker development include the regulatory approval of the proteasome inhibitor bortezomib (Velcade) and the BLA filing of the anti-angiogenic antibody mimetic pegdinetanib (Angiocept).

Research

Research Summary/Interests

  • Immunology and Inflammation drug discovery/development
  • Oncology drug discovery/development
  • PK/PD
  • Animal Disease Models
  • Development of cell-based assays

Patents

Patent #5643893: Benson, B.J., Chen, Xiannong, Cianciolo, G.J., Diaz, J.D., Ishaq, K.S., Morris-Natschke, S.L., Uhing, R.J. and Wong, H. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines. Issued July 1, 1997.

Patent #5550132: Benson, B.J., Chen, Xiannong, Cianciolo, G.J., Diaz, J.L., Ishaq, K.S., Morris-Natschke, S.L., Uhing, R.J. and Wong, H. Hydroxyalkylammonium-pryimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines. Issued August 27, 1997.

Patent #5679684: Benson, B.J., Chen, Xiannong, Cianciolo, GJ., Diaz, J.L., Ishaq, K.S., Morris-Natschke, S.L., Uhing, R.J. and Wong, H. Hydroxyalkylammonium-pyrimidines and nucleoside derivatives, useful inhibitors of inflammatory cytokines. Issued October, 21, 1997.

Publications

Wong, H.L., D.E. Wilson, J.C. Jensen, P.C. Familletti, D.L. Stremlo and M.K. Gately (1989). Characterization of a factor(s) which synergizes with recombinant interleukin-2 in promoting allogeneic human cytolytic T/ lymphocyte response in vitro. Cell. Immunol. 111:39.

Wahl, S.M., H.L. Wong and N. McCartney-Francis (1989) Role of growth factors in inflammation and repair. J. Cell. Biochem. 40:193.

Welch, G.R. H.L. Wong and S.M. Wahl (1990) Selective induction of Fc?RIII on human monocytes by transforming growth factor-?. J. Immunol. 144:3444.

Wahl, S.M., H.L. Wong, J.B. Allen and L.R. Ellingsworth (1990) Antagonistic and agonistic effects of transforming growth factor ? and IL-1 in rheumatoid arthritis. J. Immunol. 145:2514.

Allen J.B., H.L. Wong, P. Guyre, G. Simons and S.M. Wahl (1990) Circulating Fc?RIII positive monocytes in AIDS patients. Induction by transforming growth factor beta. J. Clin. Invest. 87:1773.

Wagner, D.L., H.L. Wong, M.K. Gately and D.E. Nelson (1990) Cellular source of soluble interleukin-2 receptors in serum of mice after recombinant interleukin-2 administration. Cytokines 2:337.

Wong, H.L., G.R. Welch, M.E. Brandes and S.M. Wahl (1991) Interleukin-4 (IL-4) antagonizes induction of Fc?RIII (CD16) expression by TGF-? on human monocytes. J. Immunol. 147:1843.

Wong, H.L., M.T. Lotze, L.M. Wahl and S.M. Wahl (1992) Administration of rIL-4 to humans regulates gene expression, phenotype and function in circulating monocytes. J. Immunol. 148:2118.

Wong, H.L., G.L. Costa, M.T. Lotze and S.M. Wahl (1993) Interleukin (IL) 4 differentially regulates monocyte IL-1 family gene expression and synthesis in vitro and in vivo. J.Exp. Med. 177:775.

Allen, J.B., H.L. Wong, G. Costa, M. Bienkowski and S.M. Wahl (1993) Suppression of monocyte function and differential regulation of IL-1 and IL-Ira by IL-4 contribute to resolution of experimental arthritis. J. Immunol. 151:4344.

Grisham, M.B., V.J. Palombella, P.J. Elliott, E.M. Conner, S. Brand, H.L. Wong, C. Pien, L.M. Mazzola, A. Destree, L. Parent and J. Adams (1999) Inhibition of NF-kappa B activation in vitro and in vivo : role of 26S proteasome. Methods Enzymol. 300:345.

Dineen S.P., L.A. Sullivan, A.W. Beck, A.F. Miller, J.G. Carbon, R. Mamluk, H. Wong and R.A. Brekken (2008) The adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer 8:352.

Mamluk, R., I.M. Carvajal, B.A. Morse, H. Wong, J. Abramowitz, S. Aslanian, A.c. Lim, J. Gokemeijer, M.J. Storek, J. Lee, M. Gosselin, M.C. Wright, R.T. Camphausen, J. Wang, Y. Chen, K. Miller, K. Sanders, S. Short, J. Sperinde, G. Prasad, S. Williams, R. Kerbel, J. Ebos, A. Mutsaers, J.D. Mendlein, A.S. Harris and E.S. Furfine (2010) Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. Mabs 25:2.